Results 101 to 110 of about 18,617,874 (263)

Sex‐ and Time‐Resolved Physiological and Gut Ecosystem Responses to a Food‐Grade Microbiome‐Targeted Intervention in Collegiate Endurance Athletes

open access: yesAdvanced Science, EarlyView.
In collegiate endurance athletes, a 6‐week randomized CPYE intervention yielded time‐ and sex‐dependent shifts in field‐based cardiorespiratory, metabolic, and redox indices, accompanied by changes in gut multi‐omics profiles. An exploratory extension during intensified training generates hypotheses warranting future validation.
Meng Zhang   +8 more
wiley   +1 more source

Effect of open-label placebo on exercise performance in female cyclists.

open access: yes, 2021
O efeito placebo é uma resposta psicobiológica gerada a partir da crença de que uma intervenção positiva foi recebida. A ideia de que a expectativa no tratamento e o protocolo enganoso são necessários para a geração do efeito placebo tem sido contestados
Saito, Tiemi Raquel de Moraes   +1 more
core   +1 more source

PTBP1‐Mediated Alternative Splicing of DNAJB6 Promotes Everolimus Resistance in Clear Cell Renal Cell Carcinoma via EIF4B/PKIB/AKT/mTOR Positive Feedback Loop

open access: yesAdvanced Science, EarlyView.
PTBP1‐mediated alternative splicing drives a pathogenic switch to the DNAJB6b isoform in everolimus‐resistant clear cell renal cell carcinoma. This splicing event programs a positive feedback loop including EIF4B/PKIB/AKT/mTOR, promoting aggressive therapy resistance.
Xiu‐wu Pan   +18 more
wiley   +1 more source

Changes of allergic symptoms for open-label placebo and control group (mean and standard error).

open access: yes, 2018
Patients indicated their response on a seven-point scale ranging from ‘never’ (1) to ‘always’ (7) (composite score of all symptoms). Results demonstrate significantly stronger improvement for the open-label placebo group relative to the control group ...
Benjamin Berstecher (4919128)   +2 more
core   +1 more source

Co‐activation of Selective Nicotinic Acetylcholine Receptor Subtypes Is Required for Neuroprotection against Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
ABSTRACT Beta‐amyloid peptide (Aβ)‐induced suppression of hippocampal GABAergic interneuron activity drives hyperexcitability, amyloid pathology, and cognitive impairment in Alzheimer's disease (AD), suggesting that enhancing hippocampal inhibition may be protective.
Rahmi Lee   +3 more
wiley   +1 more source

Mechanisms of open and hidden placebo in stroke recovery: targeting neuroplasticity insights of the placebo effect – study protocol for a controlled, parallel, randomised clinical trial

open access: yesBMJ Open
Introduction Stroke stands as one of the worldwide leading causes of disability, highlighting the need to develop new therapies. Although placebo effects in motor recovery have been reported to produce clinically meaningful improvements, the neural ...
Felipe Fregni   +6 more
doaj   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

open access: yesAdvanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang   +15 more
wiley   +1 more source

Open-label placebo using the example of kinesio-tape - A possible ethical alternative in physiotherapy

open access: yes, 2021
Hintergrund: Die Anwendung von Placebo sorgt seit jeher für ein ethisches Dilemma. Erste Forschungsergebnisse zu Open-label Placebo deuten jedoch darauf hin, dass Placebo sogar dann wirksam sein könnte, wenn Patient*innen ausdrücklich darüber aufgeklärt ...
Österreicher, Ivo
core   +1 more source

Single‐Cell Transcriptomic Profiling Identifies B Cell‐Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
This study generates the single‐cell atlas of pathogenic B‐cell subset Bc‐5 in ITP. It identifies RUNX3 as a key survival regulator and uncovers sphingolipid‐driven metabolic reprogramming, validating UGCG inhibition as a therapeutic candidate and building a valuable resource for ITP mechanistic and therapeutic exploration.
Dongmei Luo   +10 more
wiley   +1 more source

Drug Repurposing for Treating NCOR‐Related Intellectual Disability

open access: yesAdvanced Science, EarlyView.
An autism‐associated NCOR1 heterozygous mutation upregulates NRGs and activates NRG backward signaling in hypothalamic GABAergic neurons in mouse models, leading to Gabra2 downregulation and cognitive deficits, which can be therapeutically targeted by repurposing FDA‐approved drugs.
Yan Kong   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy